This brand name is authorized in Austria, Poland
The drug LIXIM contains one active pharmaceutical ingredient (API):
|
1
Etofenamate
UNII KZF0XM66JC - ETOFENAMATE
|
|
Etofenamate is a flufenamic acid derivative, which is readily transported through the skin and concentrated in inflamed tissue, where it exerts anti-inflammatory and analgesic effects by inhibiting the release of histamine, lysosomal enzymes and prostaglandin. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M02AA06 | Etofenamate | M Musculo-skeletal system → M02 Topical products for joint and muscular pain → M02A Topical products for joint and muscular pain → M02AA Antiinflammatory preparations, non-steroids for topical use |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100398979 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
